On May 27, 2025 BetaGlue Therapeutics S.p.A. ("BetaGlue"), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose, reported that an abstract was published by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) entitled: "Preclinical study of safety and efficacy in vivo of a yttrium-90 resin microspheres glue formulation in a large animal model of pancreatic cancer."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract describes the use of YntraDose to treat orthotopic tumors in an advanced in vivo porcine model called ‘oncopig’. Five animals were treated and followed-up over 30 days, the findings were:
No adverse events were reported throughout the study period;
YntraDose implantation and its associated radiotherapeutic payload were confined to the site of administration as demonstrated by radiological PET/CT assessment; and
At 30days visual necropsy assessment not only revealed evidence of tumor necrosis but also indicated tumor debulking.
Dr Colin Story, CEO, BetaGlue Therapeutics commented: "This study utilised a cutting edge advanced large animal model of pancreatic cancer where procedures were performed by world-renowned Interventional Radiologist and key opinion leader Professor Govindarajan Narayanan. BetaGlue is focused on bringing YntraDose to patients that present with Locally-Advanced Pancreatic Cancer which by definition is inoperable. We are very grateful to our collaborators Prof. Narayanan, Dr Geschwind and Ms Felicia Bealo for their contribution to this work."
Professor Govindarajan Narayanan, Chief of Interventional Oncology for the Miami Cancer Institute and lead author of the abstract commented: "Locally-Advanced Pancreatic Cancer (LAPC) accounts for around 30% of all Pancreatic Cancers worldwide. This study provides preliminary evidence of the utility for YntraDose as a local treatment option for LAPC with the potential to down-stage patients and enabling surgical resection to take place."
(Press release, BetaGlue Therapeutics, MAY 27, 2025, View Source [SID1234661239])